Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5104-5115

  Tai, Lee Hwa ^a   Zhang, Jiqing ^a,b,d   Scott, Karen J ^e   De Souza, Christiano Tanese ^a   Alkayyal, Almohanad A ^a,b,f   Ananth, Anu Abhirami ^a,b   Sahi, Shalini ^a   Adair, Robert A ^e   Mahmoud, Ahmad B ^b,g   Sad, Subash ^b   Bell, John C ^a,b   Makrigiannis, Andrew P ^b   Melcher, Alan A ^e   Auer, Rebecca C ^a,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d SHANDONG UNIVERSITY   (China)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSITY OF TABUK   (Saudi Arabia)

^g TAIBAH UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER SURGERY; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLUENZA VACCINATION; INNATE IMMUNITY; MELANOMA; METASTASIS; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INFLUENZA VACCINES; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PERIOPERATIVE CARE; POSTOPERATIVE PERIOD; RECEPTOR, INTERFERON ALPHA-BETA; SURGICAL PROCEDURES, OPERATIVE; TUMOR CELLS, CULTURED; VACCINATION;

EID: 84884576997     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0246     Document Type: Article

References (36)

1. Lanier LL. On guard-activating NK cell receptors. Nat Immunol 2001;2:23-7.
2. Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol 2005;17:29-35.
3. Pollock RE, Lotzova E, Stanford SD. Mechanism of surgical stress impairment of human perioperative natural killer cell cytotoxicity. Arch Surg 1991;126:338-42.
4. Pollock RE, Lotzova E, Stanford SD. Surgical stress impairs natural killer cell programming of tumor for lysis in patients with sarcomas and other solid tumors. Cancer 1992;70:2192-202.
5. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001;90:191-9.
6. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999;80:880-8.
7. Da Costa ML, Redmond P, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. Surgery 1998;124:516-25.
8. Tai LH, de Souza CT, Belanger S, Ly L, Alkayyal AA, Zhang J, et al. Preventing postoperative metastatic disease by inhibiting surgeryinduced dysfunction in natural killer cells. Cancer Res 2013;73:97-107.
9. Lukomska B, Olszewski WL, Engeset A, Kolstad P. The effect of surgery and chemotherapy on blood NK cell activity in patients with ovarian cancer. Cancer 1983;51:465-9.
10. Espi A, Arenas J, Garcia-Granero E, Marti E, Lledo S. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Dis Colon Rectum 1996;39:429-34.
11. Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010;184:2449-57.
12. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008;15:2042-52.
13. Goldfarb Y, Sorski L, Benish M, Levi B, Melamed R, Ben-Eliyahu S. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg 2011;253:798-810.
14. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987;122:1264-8.
15. Fujisawa T, Yamaguchi Y. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung. Cancer 1997;79:474-81.
16. Seth R, Tai LH, Falls T, de Souza CT, Bell JC, Carrier M, et al. Surgical stress promotes the development of cancer metastases by a coagulationdependent mechanism involving natural killer cells in a murine model. Ann Surg 2013;258:158-68.
17. Sedman PC, Ramsden CW, Brennan TG, Giles GR, Guillou PJ. Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses. Br J Surg 1988;75:976-81.
18. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapywith recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992;52:5765-9.
19. Nichols PH, Ramsden CW, Ward U, Trejdosiewicz LK, Ambrose NS, Primrose JN. Peri-operative modulation of cellular immunity in patients with colorectal cancer. Clin Exp Immunol 1993;94:4-10.
20. Deehan DJ, Heys SD, Ashby J, Eremin O. Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Surg Oncol 1995;21:16-22.
21. Houvenaeghel G, Bladou F, Blache JL, Olive D, Monges G, Jacquemier J, et al. Tolerance and feasibility of perioperative treatment with interferon-alpha 2a in advanced cancers. Int Surg 1997;82:165-9.
22. Elias D, Farace F, Triebel F, Hattchouel JM, Pignon JP, Lecesne A, et al. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum. J Am Coll Surg 1995;181:303-10.
23. Guillot B, Bessis D, Dereure O. Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf 2004;3:579-87.
24. Klatte T, Ittenson A, Rohl FW, Ecke M, Allhoff EP, Bohm M. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br J Cancer 2006;95:1167-73.
25. Oosterling SJ, van der Bij GJ, Mels AK, Beelen RH, Meijer S, van Egmond M, et al. Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients. Histol Histopathol 2006;21:753-60.
26. Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G, et al. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 2004;88:240-7.
27. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992;175:779-88.
28. Coughlin CM, Wysocka M, Trinchieri G, Lee WM. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 1997;57:2460-7.
29. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
30. Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocytederived dendritic cells. Blood 2010;116:564-74.
31. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010;59:1573-82.
32. Savory LJ, Stacker SA, Fleming SB, Niven BE, Mercer AA. Viral vascular endothelial growth factor plays a critical role in orf virus infection. J Virol 2000;74:10699-706.
33. Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010;18:888-95.
34. Patel R, Belanger S, Tai LH, Troke AD, Makrigiannis AP. Effect of Ly49 haplotype variance on NK cell function and education. J Immunol 2010;185:4783-92.
35. Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997;9:24-34.
36. Juarez-Reyes A, Noyola D, Monsivais-Urenda A, Alvarez-Quiroga C, Gonzalez-Amaro R. Influenza but not H1N1 influenza immunization is associated with changes in peripheral blood NK cell subset levels. Clin Vaccine Immunol. 2013 Jun. 19. [Epub ahead of print].